Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irinotecan hydrochloride liposome + S-1 + camrelizumab
- Development stage
- Unknown
- Lead developer
- Shandong Cancer Hospital
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
This combination regimen consists of irinotecan hydrochloride liposome, S-1 (a multi-component fluoropyrimidine), and camrelizumab (an anti-PD-1 antibody). It is primarily being investigated by the Shandong Cancer Hospital and Institute as a second-line treatment for advanced esophageal squamous cell carcinoma (ESCC). Irinotecan liposome provides sustained release of a topoisomerase I inhibitor, while S-1 acts as an antimetabolite that inhibits thymidylate synthase. Camrelizumab serves as an immune checkpoint inhibitor, blocking the interaction between PD-1 and its ligands to restore T-cell activity against tumor cells. The combination aims to provide synergistic antitumor activity through both direct cytotoxicity and immune system activation.
- Brand names
- OnivydeDuoenda
- Other names
- Camrelizumab + Irinotecan Liposome + S-1
02
Targets
DPYD (Dihydropyrimidine dehydrogenase)TS (Thymidylate synthase)TOP1 (DNA Topoisomerase I)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on irinotecan hydrochloride liposome + S-1 + camrelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irinotecan hydrochloride liposome + S-1 + camrelizumab.